Plain-English translation of NCT05882370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of two treatments—a procedure to improve blood flow in the liver (called TIPS) plus a new immunotherapy drug called —can help people with advanced liver cancer that has caused blood clots in blood vessels. is a type of immunotherapy that helps your immune system fight cancer cells. The study will follow 30 patients to see how well this treatment works and how safe it is.
Advanced liver cancer with blood vessel blockages is very hard to treat and patients have few good options. Researchers believe that combining a procedure to restore blood flow with this new immunotherapy medication might help more patients respond to treatment and live longer.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive the TIPS procedure, which restores blood flow in your liver. After that, you will receive the immunotherapy medication regularly until your cancer progresses, you experience side effects you cannot tolerate, or your doctor determines you should stop. The study will track how well your cancer responds, how long you survive, and what side effects you experience over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China